サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1446477

抗凝固剤の市場規模、シェア、動向分析レポート：薬剤分類別、投与経路別、用途別、地域別、セグメント別予測、2024年～2030年

Anticoagulants Market Size, Share & Trends Analysis Report By Route of Administration, By Drug Category, By Application, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 125 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗凝固剤の市場規模、シェア、動向分析レポート：薬剤分類別、投与経路別、用途別、地域別、セグメント別予測、2024年～2030年
出版日: 2024年02月05日
発行: Grand View Research
ページ情報: 英文 125 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗凝固剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗凝固剤市場は2030年までに604億米ドルに達すると予測され、2024年から2030年の予測期間中にCAGR 8.7％で拡大する見込みです。

同市場は主に、心血管疾患（CVD）の有病率の増加と高齢化人口の増加が原動力となっています。WHOによると、2019年、CVDは世界中で死亡の大半を引き起こし、死亡者数は1,790万人で、これは世界の死亡者数の32％を占める。このうち85％は心臓発作と脳卒中によるものです。さらに、非伝染性疾患による1,700万人の早期死亡のうち、38％がCVDによるものでした。

さらに、座りっぱなしのライフスタイルは、運動不足による血栓の世界的増加に大きく寄与しており、抗凝固剤の需要に拍車をかけています。運動不足は、肺塞栓症（PE）や深部静脈血栓症（DVT）を含む静脈血栓塞栓症（VTE）のリスク上昇に関連しています。DVTは脚の深部静脈に血栓ができたときに発症し、PEは深部静脈から肺に血栓が移動したときに発症します。米国国立医学図書館によると、DVTとPEを含むVTEは、米国で年間約90万人に影響を及ぼしています。その結果、数十万人が入院し、約30万人が死亡しています。VTEの有病率の増加と効果的な治療オプションに対する需要の高まりが、市場を押し上げると予想されます。

さらに、技術革新の促進、抗凝固剤治療の有効性と安全性の向上、患者のモニタリングと転帰の改善により、抗凝固剤市場の活性化に重要な役割を果たしています。創薬および薬剤開発の進歩により、半減期の延長、他の薬剤との相互作用の低減、出血リスクの低減などの特性が改善された新規抗凝固薬が生み出されています。これらの新規抗凝固薬は、患者により多くの治療選択肢を提供し、より良い転帰をもたらします。NIHによれば、遺伝子治療は血栓治療のための新しいアプローチであり、遺伝子を用いて血栓の原因となる根本的な遺伝子の欠陥を修正するものです。このアプローチはまだ開発の初期段階にあるが、血栓に対する効果的な治療法となる可能性を秘めています。例えば、2022年11月、FDAは第IX因子製剤を予防的に使用し、重篤な出血を繰り返している血友病Bの成人患者を治療する遺伝子治療薬Hemgenixを承認しました。これは、血液凝固第IX因子の遺伝子を肝臓に投与する1回限りの遺伝子治療です。

抗凝固剤市場レポートハイライト

  • 新規経口抗凝固薬（NOAC）は、その使いやすさとモニタリングの必要性の低減により、2023年に薬剤カテゴリーセグメントを支配し、治療計画の遵守率向上に貢献しました。
  • ヘパリンおよび低分子ヘパリン（LMWH）セグメントは、予測期間中に最も速いCAGRで成長すると予想されます。
  • 経口剤セグメントは2023年に最大の市場シェアを占め、予測期間中に最も速い成長が見込まれます。
  • 座りがちなライフスタイル、喫煙率の増加、大気汚染の増加は、心血管疾患の有病率の増加に寄与しています。
  • 心房細動/心筋梗塞（心臓発作）は、不整脈のモニタリングと管理の重要性の高まりにより、2023年の用途セグメントを支配しました。
  • 北米は、高度な医療インフラ、良好な規制環境、抗凝固療法に対する一般市民の意識の高まりなどの要因により、市場を独占しました。
  • 2022年2月、FDAはBayer AGの抗凝固薬Asundexian（BAY2433334）をFast-Track指定しました。この経口血液凝固第Xla因子阻害薬は、非心臓塞栓性虚血性脳卒中、心房細動、あるいは最近では心筋梗塞の患者における二次的血栓症の予防を目的として、現在第2相試験が進行中です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗凝固剤市場：変数、動向および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 抗凝固剤市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 抗凝固剤市場：薬剤分類の推定・動向分析

  • 薬剤分類の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 薬剤分類別の世界の抗凝固剤市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第5章 抗凝固剤市場：投与経路の推定・動向分析

  • 投与経路の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 投与経路別の世界の抗凝固剤市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第6章 抗凝固剤市場：用途の推定・動向分析

  • 用途の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 用途別の世界の抗凝固剤市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第7章 抗凝固剤市場：地域の推定・動向分析

  • 地域の市場シェア分析、2023年および2030年
  • 地域の市場ダッシュボード
  • 世界の地域の市場スナップショット
  • 市場規模と予測動向分析、2018年から2030年まで
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業別の最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • Aspen Holdings
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • GSK plc
    • Sanofi
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • DAIICHI SANKYO COMPANY, LIMITED
    • Johnson &Johnson Services, Inc.
    • Eisai Co., Ltd.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 4 North America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 7 U.S. anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 10 Canada anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 14 Europe anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 16 Germany anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 17 Germany anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Germany anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 19 UK anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 20 UK anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 21 UK anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 22 France anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 23 France anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 France anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 25 Italy anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 26 Italy anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Italy anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 28 Spain anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 29 Spain anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Spain anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 31 Denmark anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 32 Denmark anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Denmark anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 34 Sweden anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 35 Sweden anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Sweden anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 37 Norway anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 38 Norway anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Norway anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 44 China anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 45 China anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 46 China anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 47 Japan anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 48 Japan anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49 Japan anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 50 India anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 51 India anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 India anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 53 South Korea anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 54 South Korea anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 South Korea anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 56 Australia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 57 Australia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 58 Australia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 59 Thailand anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 60 Thailand anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Thailand anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 62 Latin America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 63 Latin America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Latin America surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 65 Latin America laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 66 Latin America percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 67 Latin America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 69 Brazil anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 71 Brazil laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 72 Brazil percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 73 Brazil anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 74 Mexico anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 75 Mexico anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Mexico surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 77 Mexico laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 78 Mexico percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 79 Mexico anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 80 Argentina anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 81 Argentina anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Argentina surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 83 Argentina laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 84 Argentina percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 85 Argentina anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 86 MEA anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 87 MEA anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 88 MEA anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 MEA anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 90 South Africa anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 91 South Africa anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 92 South Africa anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 94 Saudi Arabia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95 Saudi Arabia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 96 UAE anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 97 UAE anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 98 UAE anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 99 Kuwait anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 100 Kuwait anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 101 Kuwait anticoagulants market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Anticoagulants market: market outlook
  • Fig. 14 Anticoagulants competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Anticoagulants market driver impact
  • Fig. 20 Anticoagulants market restraint impact
  • Fig. 21 Anticoagulants market strategic initiatives analysis
  • Fig. 22 Anticoagulants market: Drug category movement analysis
  • Fig. 23 Anticoagulants market: Drug category outlook and key takeaways
  • Fig. 24 Novel oral anticoagulants (NOACs) market estimates and forecast, 2018 - 2030
  • Fig. 25 Heparin and Low Molecular Weight Heparin (LMWH) estimates and forecast, 2018 - 2030
  • Fig. 26 Vitamin k Antagonist market estimates and forecast, 2018 - 2030
  • Fig. 27 Direct thrombin inhibitors estimates and forecast, 2018 - 2030
  • Fig. 28 Others estimates and forecast, 2018 - 2030
  • Fig. 29 Anticoagulants Market: Route of administration movement Analysis
  • Fig. 30 Anticoagulants market: Route of administration outlook and key takeaways
  • Fig. 31 Oral anticoagulants market estimates and forecasts, 2018 - 2030
  • Fig. 32 Injectable anticoagulants market estimates and forecasts,2018 - 2030
  • Fig. 33 Anticoagulants market: Application movement analysis
  • Fig. 34 Anticoagulants market: Application outlook and key takeaways
  • Fig. 35 Atrial fibrillation/myocardial infarction (heart attack) market estimates and forecasts, 2018 - 2030
  • Fig. 36 Deep Vein Thrombosis (DVT) market estimates and forecasts,2018 - 2030
  • Fig. 37 Pulmonary embolism market estimates and forecasts, 2018 - 2030
  • Fig. 38 Other market estimates and forecasts,2018 - 2030
  • Fig. 39 Global anticoagulants market: Regional movement analysis
  • Fig. 40 Global anticoagulants market: Regional outlook and key takeaways
  • Fig. 41 Global anticoagulants market share and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America: SWOT
  • Fig. 48 Europe SWOT
  • Fig. 49 Asia Pacific SWOT
  • Fig. 50 Latin America SWOT
  • Fig. 51 MEA SWOT
  • Fig. 52 North America, by country
  • Fig. 53 North America
  • Fig. 54 North America market estimates and forecasts, 2018 - 2030
  • Fig. 55 U.S. key country dynamics
  • Fig. 56 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 57 Canada key country dynamics
  • Fig. 58 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 59 Europe
  • Fig. 60 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 61 UK key country dynamics
  • Fig. 62 UK market estimates and forecasts, 2018 - 2030
  • Fig. 63 Germany key country dynamics
  • Fig. 64 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 65 France key country dynamics
  • Fig. 66 France market estimates and forecasts, 2018 - 2030
  • Fig. 67 Italy key country dynamics
  • Fig. 68 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 69 Spain key country dynamics
  • Fig. 70 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 71 Denmark key country dynamics
  • Fig. 72 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 73 Sweden key country dynamics
  • Fig. 74 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 75 Norway key country dynamics
  • Fig. 76 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 77 Asia Pacific
  • Fig. 78 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 79 China key country dynamics
  • Fig. 80 China market estimates and forecasts, 2018 - 2030
  • Fig. 81 Japan key country dynamics
  • Fig. 82 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 83 India key country dynamics
  • Fig. 84 India market estimates and forecasts, 2018 - 2030
  • Fig. 85 Thailand key country dynamics
  • Fig. 86 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 87 South Korea key country dynamics
  • Fig. 88 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 89 Australia key country dynamics
  • Fig. 90 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 91 Latin America
  • Fig. 92 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 93 Brazil key country dynamics
  • Fig. 94 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 95 Mexico key country dynamics
  • Fig. 96 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 97 Argentina key country dynamics
  • Fig. 98 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 99 Middle East and Africa
  • Fig. 100 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 101 South Africa key country dynamics
  • Fig. 102 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 103 Saudi Arabia key country dynamics
  • Fig. 104 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 105 UAE key country dynamics
  • Fig. 106 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 107 Kuwait key country dynamics
  • Fig. 108 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 109 Market share of key market players- Anticoagulants market
目次
Product Code: GVR-4-68040-191-0

Anticoagulants Market Growth & Trends:

The global anticoagulants market is anticipated to reach USD 60.4 billion by 2030 and is expected to expand at a CAGR of 8.7% during the forecast period of 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and growing aging population. According to WHO, in 2019, CVDs caused majority of deaths worldwide, accounting for 17.9 million fatalities, which is 32% of global deaths. Among these deaths, 85% were attributed to heart attack and stroke. Moreover, of the 17 million premature deaths caused by noncommunicable diseases, 38% were due to CVDs in the same year.

Moreover, sedentary lifestyles significantly contribute to the global rise of blood clots owing to physical inactivity, fueling the demand for anticoagulants. Physical inactivity has been linked to an increased risk of venous thromboembolism (VTE), a condition that encompasses pulmonary embolism (PE) and deep vein thrombosis (DVT). The condition arises when a blood clot occurs in a deep vein in the legs, while PE occurs when a blood clot travels from a deep vein to the lungs. As per the National Library of Medicine, VTE, which includes DVT and PE, impacts around 900,000 individuals in the U.S. annually. This led to several hundred thousand hospitalizations and approximately 300,000 deaths. The increasing prevalence of VTE and the growing demand for effective treatment options is expected to boost the market.

Furthermore, technological advancements are playing a significant role in boosting the anticoagulants market by driving innovation, improving the efficacy and safety of anticoagulant treatments, and enhancing patient monitoring and outcomes. Advancements in drug discovery and development have led to the creation of new anticoagulants with improved properties, such as longer half-lives, fewer interactions with other medications, and reduced bleeding risks. These novel anticoagulants offer patients more treatment options and better outcomes. According to NIH, gene therapy is a new approach for treatment of blood clots that involves the use of genes to correct the underlying genetic defect that causes clotting. This approach is still in its early stage of development but has potential to be an effective treatment for blood clots. For instance, in November 2022, the FDA approved Hemgenix, a gene therapy to treat adults with hemophilia B who are using Factor IX prophylaxis and have a history of repeated, serious bleeding episodes. It is a one-time gene therapy that delivers a gene for clotting factor IX to the liver.

Anticoagulants Market Report Highlights:

  • Novel oral anticoagulants (NOACs) dominated the drug category segment in 2023 owing to their ease of use and reduced need for monitoring, contributing to better adherence to treatment plans
  • The Heparin and Low Molecular Weight Heparin (LMWH) segment is expected to grow at the fastest CAGR over the forecast period.
  • The oral segment held the largest market share in 2023 and is expected to witness fastest growth over the forecast period.
  • Sedentary lifestyle, increasing incidence of smoking, and rising air pollution are contributing to the growing prevalence of cardiovascular diseases
  • Atrial fibrillation/myocardial infarction (Heart attack) dominated the application segment in 2023 owing to rising importance of monitoring and managing arrhythmia
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, favorable regulatory environment and rising public awareness of anticoagulant therapy
  • In February 2022, FDA granted Bayer AG's anticoagulant Asundexian (BAY2433334) Fast-Track designation. The oral factor Xla inhibitor is currently undergoing phase 2 trials for the potential prevention of secondary thrombosis in patients with non-cardioembolic ischemic stroke, atrial fibrillation, or more recently myocardial infarction.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug category
    • 1.2.2. Route of administration
    • 1.2.3. Application
  • 1.3. Regional scope
  • 1.4. Estimates and forecasts timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased database
    • 1.6.2. GVR's internal database
    • 1.6.3. Secondary sources
    • 1.6.4. Primary research
    • 1.6.5. Details of primary research
      • 1.6.5.1. Data for primary interviews in North America
      • 1.6.5.2. Data for primary interviews in Europe
      • 1.6.5.3. Data for primary interviews in Asia Pacific
      • 1.6.5.4. Data for primary interviews in Latin America
      • 1.6.5.5. Data for Primary interviews in MEA
  • 1.7. Information or Data Analysis
    • 1.7.1. Data analysis models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity flow analysis (Model 1)
    • 1.9.2. Approach 1: Commodity flow approach
    • 1.9.3. Volume price analysis (Model 2)
    • 1.9.4. Approach 2: Volume price analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Primary Sources
  • 1.12. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Treatment outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anticoagulants Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases
      • 3.2.1.2. Technological advancements in development of anticoagulant products
      • 3.2.1.3. Growing adoption of Novel Oral Anticoagulants (NOACs)
      • 3.2.1.4. Rising geriatric population and increase prevalence of obesity
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High price associated with Novel Oral Anticoagulants (NOACs)
      • 3.2.2.2. Stringent government regulations and poor demand in underdeveloped countries
  • 3.3. Anticoagulants Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis

  • 4.1. Drug Category Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Anticoagulants Market by Drug Category Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Novel oral anticoagulants (NOACs)
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Eliquis
      • 4.4.1.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Xarelto
      • 4.4.1.5. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.6. Savaysa & Lixiana
      • 4.4.1.7. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.8. Pradaxa
      • 4.4.1.9. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Heparin and Low Molecular Weight Heparin (LMWH)
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Vitamin k Antagonist
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Direct thrombin inhibitors
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Route of Administration Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Anticoagulants Market by Treatment Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Oral anticoagulants
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Injectable anticoagulants
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Anticoagulants Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Deep Vein Thrombosis (DVT)
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Pulmonary Embolism
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Others
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Aspen Holdings
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Pfizer Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Bristol-Myers Squibb Company
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. GSK plc
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Sanofi
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Bayer AG
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Boehringer Ingelheim International GmbH
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. DAIICHI SANKYO COMPANY, LIMITED
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Johnson & Johnson Services, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Eisai Co., Ltd.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives